AstraZeneca Investor Day Presentation Deck
Imfinzi and
tremelimumab
Phase II data in gastrointestinal cancers informed TOPAZ-1 and HIMALAYA designs
Phase II trial in biliary tract cancer
A
Canon 2
Study 22¹ HCC T-cell proliferation data
31
2-
-1
-2-
-3
4
T75+ D
-2 0
Canon 1: CD4+ populations
Canon 2: CD8+ populations
T300 + D
2
Canon 1
4
T
6 8
B
100-
80
60
20
0
T300 + D
CR/PR SD PD
Median 47 20.5 24
Count 9 18 19
CR/PR
38
3
D
SD
12
9
Day 15
PD
13
23
CR/PR
35
1
T
SD
26
7
PD
20
8
• 322 patients with advanced hepatocellular
carcinoma randomised between arms
T75+ D
CR/PR SD PD
21.5 14 13
2
8 18
Median OS: T300+D - 18.7-mo; Imfinzi - 13.6-mo
• 121 patients enrolled with 1st-line biliary
tract cancer
• Imfinzi (+/- tremelimumab) in
combination with gemcitabine and
cisplatin
• Combination was well tolerated
●
Median OS: 18.1-mo for Imfinzi + gem/cis
8
1. Kelley et al J Clin Oncol 39, 27: 2021 2991-3001 2. D-Y Oh et al ASCO 2020 J Clin Oncol 38, 15 suppl: 2020 4520. OS = overall survival; T300 = tremelimumab 300mg; mo = months; gem - = gemcitabine; cis = cisplatinView entire presentation